Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000600011 |
Resumo: | OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea treatment is undeniable in sickle cell disease with monitoring of the biological action of the drug being by the complete blood count. The objective of this work is to compare changes in some of the erythrocytic indexes between S/Beta thalassemia and sickle cell anemia patients on long-term hydroxyurea treatment. METHODS: The values of erythrocyte indexes (mean corpuscular volume and mean corpuscular hemoglobin) were compared in a retrospective study of two groups of patients (Sickle cell anemia and S/Beta thalassemia) on hydroxyurea treatment over a mean of six years. RESULTS: The quantitative values of the two parameters differed between the groups. Increases in mean corpuscular volume and reductions in mean corpuscular hemoglobin delay longer in S/Beta thalassemia patients (p-value = 0.018). CONCLUSION: Hematological changes are some of the beneficial effects of hydroxyurea in sickle cell disease as cellular hydration increases and the hemoglobin S concentration is reduced. The complete blood count is the best test to monitor changes, but the interpretation of the results in S/Beta thalassemia should be different. |
id |
ABHHTC-1_68e5f662e39c220a054b89226bf1faba |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842012000600011 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatmentAnemia, sickle cellHydroxyureaHemoglobinopathiesErythrocyte indicesOBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea treatment is undeniable in sickle cell disease with monitoring of the biological action of the drug being by the complete blood count. The objective of this work is to compare changes in some of the erythrocytic indexes between S/Beta thalassemia and sickle cell anemia patients on long-term hydroxyurea treatment. METHODS: The values of erythrocyte indexes (mean corpuscular volume and mean corpuscular hemoglobin) were compared in a retrospective study of two groups of patients (Sickle cell anemia and S/Beta thalassemia) on hydroxyurea treatment over a mean of six years. RESULTS: The quantitative values of the two parameters differed between the groups. Increases in mean corpuscular volume and reductions in mean corpuscular hemoglobin delay longer in S/Beta thalassemia patients (p-value = 0.018). CONCLUSION: Hematological changes are some of the beneficial effects of hydroxyurea in sickle cell disease as cellular hydration increases and the hemoglobin S concentration is reduced. The complete blood count is the best test to monitor changes, but the interpretation of the results in S/Beta thalassemia should be different.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000600011Revista Brasileira de Hematologia e Hemoterapia v.34 n.6 2012reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20120107info:eu-repo/semantics/openAccessNeves,FabiaMenezes Neto,Osvaldo AlvesPolis,Larissa BuenoBassi,Sarah CristinaBrunetta,Denise MenezesSilva-Pinto,Ana CristinaAngulo,Ivan Lucenaeng2013-01-21T00:00:00Zoai:scielo:S1516-84842012000600011Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2013-01-21T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
title |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
spellingShingle |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment Neves,Fabia Anemia, sickle cell Hydroxyurea Hemoglobinopathies Erythrocyte indices |
title_short |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
title_full |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
title_fullStr |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
title_full_unstemmed |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
title_sort |
Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment |
author |
Neves,Fabia |
author_facet |
Neves,Fabia Menezes Neto,Osvaldo Alves Polis,Larissa Bueno Bassi,Sarah Cristina Brunetta,Denise Menezes Silva-Pinto,Ana Cristina Angulo,Ivan Lucena |
author_role |
author |
author2 |
Menezes Neto,Osvaldo Alves Polis,Larissa Bueno Bassi,Sarah Cristina Brunetta,Denise Menezes Silva-Pinto,Ana Cristina Angulo,Ivan Lucena |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Neves,Fabia Menezes Neto,Osvaldo Alves Polis,Larissa Bueno Bassi,Sarah Cristina Brunetta,Denise Menezes Silva-Pinto,Ana Cristina Angulo,Ivan Lucena |
dc.subject.por.fl_str_mv |
Anemia, sickle cell Hydroxyurea Hemoglobinopathies Erythrocyte indices |
topic |
Anemia, sickle cell Hydroxyurea Hemoglobinopathies Erythrocyte indices |
description |
OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea treatment is undeniable in sickle cell disease with monitoring of the biological action of the drug being by the complete blood count. The objective of this work is to compare changes in some of the erythrocytic indexes between S/Beta thalassemia and sickle cell anemia patients on long-term hydroxyurea treatment. METHODS: The values of erythrocyte indexes (mean corpuscular volume and mean corpuscular hemoglobin) were compared in a retrospective study of two groups of patients (Sickle cell anemia and S/Beta thalassemia) on hydroxyurea treatment over a mean of six years. RESULTS: The quantitative values of the two parameters differed between the groups. Increases in mean corpuscular volume and reductions in mean corpuscular hemoglobin delay longer in S/Beta thalassemia patients (p-value = 0.018). CONCLUSION: Hematological changes are some of the beneficial effects of hydroxyurea in sickle cell disease as cellular hydration increases and the hemoglobin S concentration is reduced. The complete blood count is the best test to monitor changes, but the interpretation of the results in S/Beta thalassemia should be different. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000600011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000600011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5581/1516-8484.20120107 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.34 n.6 2012 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213111641931776 |